Clinical Trial Update: A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This is a pediatric and young adult Phase 1/2 clinical trial evaluating a CD22-directed CAR-T cell therapy for relapsed or refractory leukemia or lymphoma. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CD22-directed CAR-T cell therapy

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING